FOXO4-DRI is a synthetic peptide commonly explored in provider-directed longevity and healthy-aging research programs. It is frequently considered in programs focused on senescent cell research, longevity research, and healthy-aging research, and should be evaluated based on the individual patient, treatment objective, and applicable prescribing information.
What It Is Used For
FOXO4-DRI is commonly considered in provider-directed longevity and healthy-aging research programs focused on the following areas of interest:
Senescent Cell Research — Often considered in provider-directed programs focused on senescent cell research and cellular-aging pathways.
Longevity Research — May be explored within programs designed to investigate longevity-related biological pathways.
Healthy-Aging Research — May be considered for patients whose goals include healthy-aging research and related wellness objectives.
FOXO4-DRI is not FDA-approved for the treatment, cure, or prevention of disease. Information provided by ALML is intended for healthcare professionals and does not replace independent clinical judgment.
How It Works
FOXO4-DRI is a synthetic D-amino-acid peptide (retro-inverso) designed to interact with the FOXO4 transcription factor pathway. Preclinical research has investigated its association with senescent-cell biology.
Areas being studied include:
FOXO4/p53 Interaction — Preclinical research has examined FOXO4-DRI's interference with the FOXO4–p53 interaction, a pathway studied in the context of senescent cell persistence.
Senescent Cell Pathways — Animal research has explored potential effects on cellular senescence and the selective targeting of senescent cells.
Cellular-Aging Biology — Research has investigated associations with biological pathways involved in cellular aging and longevity.
Evidence for FOXO4-DRI remains primarily preclinical. These mechanisms have not established clinical efficacy or safety in humans, and FOXO4-DRI is not FDA-approved.
Clinical Information
FOXO4-DRI remains an investigational peptide with limited human clinical evidence. Healthcare professionals should independently evaluate the available evidence, patient-specific factors, potential risks, and applicable regulatory requirements before considering its use.
Include these considerations:
Limited Human Evidence — Published evidence is largely preclinical, and well-controlled human clinical data establishing safety and efficacy are limited.
Not FDA-Approved — FOXO4-DRI is not FDA-approved for the diagnosis, treatment, cure, or prevention of any disease or medical condition.
Safety Profile Not Established — Long-term safety, adverse-event frequency, drug interactions, and risks in specific patient populations have not been fully established.
Professional Judgment — Treatment and prescribing decisions remain solely the responsibility of the appropriately licensed healthcare professional.
ALML provides product and educational information for healthcare professionals. This information is not a substitute for prescribing information, pharmacy labeling, applicable law, or independent clinical judgment.
Available Options
Option 1
Verified formulations and strengths will be updated based on current pharmacy availability.
Dosing & Reconstitution
For provider use only. Calculates reconstitution math — does not select or recommend a patient dose.
Product Dosing Schedule
Provider Inputs
Calculated Outputs
Concentration
—
Medication amount ÷ diluent mL
Volume to Draw
—
Desired dose ÷ concentration
U-100 Syringe Units
—
Volume to draw × 100 — 100 syringe units = 1.00 mL · 1 syringe unit = 0.01 mL
| Frequency | Daily |
| Dose Unit | mg/day |
| Administrations Per Week | 7 |
Dosing information is provided for healthcare-professional reference only when verified. Patient-specific dosing and prescribing decisions remain the responsibility of the treating healthcare professional.
This tool performs reconstitution/administration math only. It does not select, recommend, or validate a patient dose. Dosing decisions are the responsibility of the prescribing healthcare provider.
Ask ALML
Ask ALML may identify FOXO4-DRI as a product for a healthcare professional to explore when the described patient goals involve senescent cell research, longevity research, or healthy-aging research.
The match is informational. Ask ALML is designed to help healthcare professionals navigate the ALML portfolio and identify potentially relevant options for further clinical consideration. It does not diagnose a patient, prescribe treatment, determine medical necessity, or select patient-specific dosing.
Submit an order request or ask about availability. A request is not a guaranteed order — every inquiry goes to ALML staff for manual review and follow-up.
ALML does not guarantee that any specific therapy can be supplied. Availability is confirmed through manual review of each request.